Reviews/Heart Failure Management/Vericiguat neutral for primary endpoint in stable heart failure with reduced ejection fraction
Novel · HFM-NOVEL-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
A large, dedicated trial [3] tested vericiguat in patients with reduced-ejection-fraction heart failure who were stable and had not recently deteriorated. In this group the main combined measure of cardiovascular death or heart-failure hospitalisation was not reduced to a degree that reached statistical significance. A separate trial [2] in patients who HAD recently worsened did show a significant reduction in the same combined measure, so the result depends on which population is being treated. The panel accepted the claim because it restates the trial's own pre-specified primary finding in exactly the population the claim names. The main caution is that the whole conclusion rests on one trial, and that cardiovascular death alone did move in vericiguat's favour, so 'no significant effect on the composite' should not be read as 'no effect at all'.
The VICTOR trial [3] randomised 6105 patients with HFrEF and no recent worsening and found the primary composite of cardiovascular death or heart-failure hospitalisation occurred in 549 (18.0%) vericiguat versus 584 (19.1%) placebo patients (HR 0.93, 95% CI 0.83-1.04, p=0.22), a non-significant result. The same trial's mortality analysis [8] states vericiguat 'was neutral for the primary composite endpoint.' In contrast, VICTORIA [2], in patients with recent worsening, found the same composite significantly reduced (HR 0.90, 95% CI 0.82-0.98, P=0.02), establishing that the direction of the result tracks the population. Notably within VICTOR [3], cardiovascular death alone was lower with vericiguat (HR 0.83, 95% CI 0.71-0.97), as was all-cause death (HR 0.84, 95% CI 0.74-0.97). The contested point: The division is between the neutral composite and its components: the composite was non-significant (HR 0.93) in [3], yet cardiovascular death alone was nominally lower (HR 0.83) in the same trial, so 'does not significantly reduce the composite' is a statement about the composite's significance and not about biological inactivity. The pooled analysis [5] reports a significant combined-population benefit (HR 0.91, p=0.0088) but merges worsening and no-worsening patients, so it neither isolates nor rebuts the claim's population.
All 24 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Heart Failure Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim rests essentially on a single trial: VICTOR [3]. Paper [8] is a pre-specified secondary analysis of the same trial and the same 6105 patients, not independent corroboration, so there is no second trial in the claim population.
Directional overreach risk: the point estimate HR 0.93 favours vericiguat, the 95% CI (0.83-1.04) still includes a clinically meaningful 17% reduction, and CV death alone was nominally reduced (HR 0.83). 'Does not significantly reduce' is accurate only as a statement about statistical significance of the composite and must not be read as 'no effect'.
Where it remains uncertain. The composite was neutral, yet cardiovascular death alone was nominally lower with vericiguat (HR 0.83, 95% CI 0.71-0.97) in the same trial [3], and the result is reversed in the recent-worsening population of VICTORIA [2] (HR 0.90, P=0.02).
Aleatory
The point estimate HR 0.93 in [3] favours vericiguat and the 95% CI upper bound (1.04) sits just above 1, so the neutral verdict reflects a result close to the threshold rather than a clearly null effect.
Epistemic
Only VICTOR [3] tests the exact no-worsening population; [8] is a same-trial analysis of the same 6105 patients, so no independent replication exists in the corpus.
Inferential
The composite is neutral in [3] while cardiovascular death alone is nominally lower (HR 0.83), so inferring 'no benefit' from the composite overreaches the component evidence.
The load-bearing papers from a corpus of 24, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Contrast case: in the recent-worsening population the same composite WAS significantly reduced, confirming the claim is specific to the no-worsening population.
“a primary-outcome event occurred in 897 of 2526 patients (35.5%) in the vericiguat group and in 972 of 2524 patients (38.5%) in the placebo group (hazard ratio, 0.90; 95% confidence interval [CI], 0.82 to 0.98; P = 0.02)”
Panel auditInternal validity: high · scope of inference: Vericiguat versus placebo in high-risk HFrEF with recent hospitalisation or IV diuretic use.Key limitations: wrong population (recent worsening) · does not isolate stable patients
Directly confirms the claim: the primary composite is not significantly reduced in the exact claim population.
“Among patients with HFrEF and no recent worsening, vericiguat did not reduce the risk of a composite endpoint of time to cardiovascular death or heart failure hospitalisation.”
Panel auditInternal validity: high · scope of inference: Vericiguat versus placebo in HFrEF (LVEF <=40%) without HF hospitalisation within 6 months or outpatient IV diuretics within 3 months.Key limitations: secondary endpoints nominal only · open question whether CV-death signal is real given neutral composite
Reaffirms neutrality of the primary composite (same trial, not independent).
Panel auditInternal validity: high · scope of inference: Mortality effects of vericiguat in ambulatory HFrEF without recent worsening; composite endpoint neutral.Key limitations: composite stated only as neutral without CI here · paper's own focus is the secondary mortality endpoint
3 of 24 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A large, pre-registered, double-blind RCT reporting its pre-specified primary composite as non-significant in the exact claim population directly and robustly carries this negative claim, warranting Established tier tempered only by single-trial dependence.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No independent replication in the no-worsening population. The claim rests on a single trial [3] (with same-trial analysis [8]); a confirmatory finding from a different cohort would test whether the neutral composite is robust or a near-threshold single-trial result. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A second adequately powered RCT of vericiguat in stable HFrEF without recent worsening, with the same composite primary endpoint.
Open question: Does the neutral primary composite in stable HFrEF without recent worsening replicate in an independent trial? Why it is still open: Only VICTOR [3] and its own analysis [8] test this population; no independent cohort is present in the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19